ASTD: The Alternative Splicing and Transcript Diversity database  by Koscielny, Gautier et al.
Genomics 93 (2009) 213–220
Contents lists available at ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r.com/ locate /ygenoASTD: The Alternative Splicing and Transcript Diversity database
Gautier Koscielny a, Vincent Le Texier a, Chellappa Gopalakrishnan a, Vasudev Kumanduri a,
Jean-Jack Riethoven a,1, Francesco Nardone a,2, Eleanor Stanley a, Christine Fallsehr b, Oliver Hofmann c,
Meelis Kull d,e, Eoghan Harrington f, Stéphanie Boué f, Eduardo Eyras g, Mireya Plass g, Fabrice Lopez h,
William Ritchie h, Virginie Moucadel h,3, Takeshi Ara h,4, Heike Pospisil i, Alexander Herrmann j,
Jens G. Reich k, Roderic Guigó g,l, Peer Bork f, Magnus von Knebel Doeberitz b, Jaak Vilo d,e, Winston Hide c,
Rolf Apweiler a, Thangavel Alphonse Thanaraj a,5, Daniel Gautheret h,⁎,6
a European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
b Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 220, D-69120 Heidelberg, Germany
c South African National Bioinformatics Institute, University Western Cape, Private Bag X17, Bellville 7535, South Africa
d Estonian Biocenter, Riia 23b, 51010 Tartu, Estonia
e University of Tartu, Liivi 2, 50409 Tartu, Estonia
f Structural and Computational Biology Unit, European Molecular Biology Laboratory, Meyerhofstraβe 1, 69117 Heidelberg, Germany
g Grup de Recerca en Informatica Biomedica, Institut Municipal d'Investigacio Medica, Universistat Pompeu Fabra, Plaça de la Mercè, 10-12, 08002 Barcelona, Spain
h INSERM U928, Université de la Méditerranée, case 928 - 163, Avenue de Luminy, 13288 Marseille cedex 09, France
i Center for Bioinformatics, University of Hamburg, Bundesstr.43, 20146 Hamburg, Germany
j Institute for Clinical Molecular Biology, Christian-Albrechts University Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany
k Dept. of Bioinformatics, Max-Delbrueck-Center for Molecular Medicine Berlin-Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany
l Center for Genomic Regulation, C/ Dr. Aiguader, 88 - 08003 Barcelona, Spain⁎ Corresponding author. Fax: +33 1 69 15 46 29.
E-mail address: daniel.gautheret@u-psud.fr (D. Gaut
1 Current address: Center for Biotechnology, Univers
Vine Street, Lincoln, NE 68588, USA.
2 Current address: WebOn ASm Postboks 2198, 3103
3 Current address: Laboratoire de Transduction du Si
Technologies et Sciences pour le Vivant – CEA, 17 Rue
France.
4 Current address: Kazusa DNA Research Institute, 2-6
Chiba 292-0818, Japan.
5 Current address: CRS4-Bioinformatica, Parco Scient
Ediﬁcio 3, 09010 Pula (CA), Sardinia, Italy.
6 Current address: Univ. Paris-Sud 11, CNRS, UMR862
France.
0888-7543/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.ygeno.2008.11.003a b s t r a c ta r t i c l e i n f oArticle history: The Alternative Splicing and
Received 24 April 2008
Accepted 5 November 2008
Available online 24 December 2008
Keywords:
Alternative transcription
Alternative splicing
Alternative polyadenylation
Alternative initiationTranscript Diversity database (ASTD) gives access to a vast collection of alternative
transcripts that integrate transcription initiation, polyadenylation and splicing variant data. Alternative
transcripts are derived from the mapping of transcribed sequences to the complete human, mouse and rat
genomes using an extension of the computational pipeline developed for the ASD (Alternative Splicing
Database) and ATD (Alternative Transcript Diversity) databases, which are now superseded by ASTD. For the
humangenome, ASTD identiﬁes splicing variants, transcription initiationvariants andpolyadenylation variants
in 68%, 68% and 62% of the gene set, respectively, consistent with current estimates for transcription variation.
Users can access ASTD through a variety of browsing and query tools, including expression state-based queries
for the identiﬁcation of tissue-speciﬁc isoforms. Participating laboratories have experimentally validated a
subset of ASTD-predicted alternative splice forms and alternative polyadenylation forms that were not
previously reported. The ASTD database can be accessed at http://www.ebi.ac.uk/astd.
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Transcript expression in eukaryotes is subject to variation at three
main biological stages: transcription initiation, splicing and polyade-
nylation. In mammals, most genes undergo some kind of alternative
transcription. Current data for human indicates that at least 81% of
genes are subject to alternative transcription initiation [1], 69% to
alternative splicing [2] and 60% to alternative polyadenylation [3].
Abnormal expression of alternative transcripts has been linked to
multiple diseases, especially to cancer [4]. The sheer number andwide
biological impact of alternative transcripts (ATs) has created a high
demand for tools enabling the identiﬁcation, classiﬁcation, functional
annotation and expression proﬁling of ATs in the genomes of major
model organisms. To meet this demand, several AT databases have
been developed based on large-scale mappings or assemblies of
Fig. 1. Flowchart of the ASTD production pipeline.
Table 2
Comparison of alternative splicing analyses with other databases
Database Species Genes alternatively spliced Genes spliced Exons
ASAP IIa Human 11,717 (53%) 22,220 129,981
b
214 G. Koscielny et al. / Genomics 93 (2009) 213–220transcribed sequences. These include alternative splicing databases
such as ASAP II [5], ECGene [6], HOLLYWOOD [7], H-DBAS [8] and FAST
DB [9], the FANTOM 3 database [10] that also features transcription
initiation variants in the form of Cap-analysis gene expression (CAGE)
tags, and the polyadenylation-speciﬁc PolyA_DB [3].
Here we report the development of ASTD, the Alternative Splicing
and Transcript Diversity database, which aims at further integrating
data from all three types of transcript variation together with
extensive biological and expression information. ASTD is built upon
and supersedes the splicing-oriented ASD database [11] and the ATD
database that included 3′ end variations [12]. The Alternative
Transcript Diversity Consortium that produced this new database
involves laboratories working on various aspects of alternative
transcript analysis, both computational and experimental. Our goal
was to create an alternative transcript database that: (i) covers all
three aspects of alternative transcription; (ii) includes three model
vertebrate species and allows for expansion to include new species;Table 1
Release statistics for ASTD version 1.1
Human Mouse Rat
Genes with an ASTD transcript 16,710 16,491 10,424
Genes with an ASTD transcription start site 13,265 11,161 1906
Genes with an ASTD polyA site 15,376 13,556 8842
Genes with an ASTD splice event 11,316 9474 2865
Genes with multiple TSSs 11,340 8150 4
Genes with splice events and multiple TSSs 10,145 8462 1
Genes showing splice events and multiple polyA sites 7607 4352 1275
Percentage of genesa undergoing alternative splicing 68% 57% 27%
Percentage of genesa undergoing alternative polyadenylation 92% 82% 85%
Percentage of genes undergoing multiple TSS positions 68% 49% 0.04%
a The number of protein coding genes with alternative forms as a percentage of the
total number of protein coding genes in ASTD.(iii) offers a powerful interface for expression pattern-based queries;
(iv) is fully integrated with other genomic data and genome browsing
capabilities and (v) is extensible with respect to functional features
and regulatory motifs.
Results and discussion
Contents and comparisons with other transcript databases
The ASTD alternative transcript collection is built through three
successive stages of transcript-to-genome mapping corresponding toECGene Human 21,419 (45%) 47,943 –
Hollywoodc Human – – 151,199
ASTD Human 14,101 (84%) 16,715 325,692
ASAP II Mouse 8711 (53%) 16,404 105,260
ECGene Mouse 19,361 (50%) 38,864 –
Hollywood Mouse – – 90,885
ASTD Mouse 13,028 (79%) 16,491 275,612
ASAP II Rat 3378 (24%) 14,195 61,303
ECGene Rat 11,005 (39%) 27,975 –
ASTD Rat 6344 (61%) 10,424 122,593
a From ASAP II [5]. Genome assemblies: NCBI human Build 35 (UCSC version hg17),
NCBI mouse Build 35 (UCSC version mm7), and RGSC rat Build 3.1 (UCSC version rn3).
b From the ECGene web site (http://genome.ewha.ac.kr/ECgene). Part A+B+C of
database. Genome assemblies: NCBI human Build 36 (UCSC version hg18), NCBI mouse
build 36 (UCSC version mm8), and RGSC rat Build 3.4 (UCSC version rn4).
c Exon number obtained from current statistics on http://hollywood.mit.edu/Logo/
Fig_2.png. Genome assemblies: NCBI human Build 34 (UCSC version hg16) and NCBI
mouse build 34 (UCSC version mm3).
215G. Koscielny et al. / Genomics 93 (2009) 213–220splicing (AltSplice), polyadenylation (AltTrans and AltPAS) and
transcriptional start site (AltTSS) variant prediction. AltTrans identi-
ﬁes polyadenylation sites corresponding to speciﬁc splice patterns
while AltPAS identiﬁes other potential polyA sites irrespective of
underlying splice patterns. Each program maps a speciﬁc set of
complementary DNA (cDNA) or expressed sequence tags (ESTs) toFig. 2. Gene view for human polypyrimidine tract binding protein 1 gene PTBP1 (Ensembl
show transcript variants present in the Ensembl database and the next lines show ASTD vari
respective signal sequence. Dark dots indicate premature termination codons present in i
exons (arrows, described in literature as exons 9 and 11) and cause NMD.genome sequences, using protocols detailed in the Materials and
methods section. The “Expression Proﬁles” pipeline associates each
cDNA or sequence tag to anatomical/disease/development terms
(expression states) and computes the expression proﬁle of each
alternative transcript based on numbers of cDNAs or tags supporting
this transcript. Currently, expression proﬁles are computed for spliceID ENSG00000011304.8). Each line presents a transcript isoform. The ﬁrst three lines
ants. Alternative polyadenylation sites supported by cDNA data are presented with their
nternal exons that may lead to NMD. Transcript TRAN00000039923 has two skipped
216 G. Koscielny et al. / Genomics 93 (2009) 213–220variants only, but the procedure will eventually be extended to
initiation and polyadenylation variants. The process is entirely
automated, except for the derivation of expression states from novel
cDNA/tag libraries that requires human curation. A ﬂowchart
presenting the general ASTD pipeline is shown in Fig. 1.
Table 1 presents the number of splicing, polyadenylation and
transcriptional start site (TSS) variants per species in ASTD Version 1.1.
The predicted fraction of genes with polyadenylation variants exceeds
current estimates [3] mostly because ASTD also includes putative
polyadenylation signals in the 10 kb downstream of region of reference
gene models [13]. Splice and TSS variant frequencies are in line with
current estimates, except for rat,which shows fewer events due to scarce
EST/cDNA coverage in this species, especially for the 5′ region of genes.
Table 2 compares ASTD splice variant statistics with corresponding
values from three major AT databases. ASTD contains more alternative
splicing events and/or mapped exons than ASAP II and Hollywood. This
reﬂects multiple factors such as the use of more recent EST/genome
database versions in ASTD and differences in the transcript mapping
procedures. ECgene harbours signiﬁcantlymore genes and splice events
than any other database due to their transcript construction procedure
based on EST clustering. In Supplementary Table 1, we compare the
numbers of alternatively spliced genes and proportions of different
event types (cassette exons, alternative 5′ or 3′ sites, mutually exclusive
exons) between the ASTD and ASAP II database. While ASTD has
signiﬁcantly higher splice event coverage in mouse and rat, event types
are similarly distributed in the two databases: cassette exons are more
frequent, followed by variations at donor/acceptor sites.
The ASTD database integrates Ensembl [14] features such as
transcripts, exons and peptides, enabling comparison of ASTD and
Ensembl predictions. Other transcript information and crosslinks
include conserved splice junctions and splice events in human, mouse
and rat; single nucleotide polymorphism (SNP) locations; transcripts
with premature termination codons (PTCs) that may be subject to
nonsense-mediated decay (NMD); microRNA targets; and peptide
data, including for each variant the peptide sequence, domains and
functional site signatures.
Display and query tools
ASTD offers multiple visualization levels, from complete chromo-
some map to the levels of genomic fragment, gene, transcript, splicing
event and peptide. Users can easily navigate between different views,
starting either from genomic coordinates or keyword search. Themain
visualization levels are the gene view showing all transcript isoforms,
the transcript view displaying detailed exon information and the
“event” view displaying independent alternative splicing events. Fig. 2
presents the gene view for the human polypyrimidine tract binding
protein 1 gene (PTBP1), a splicing factor known to autoregulate its
own splicing. A form lacking exons 9 and 11 is reported to undergo
NMD and may contribute to the control of PTBP1 expression [15].
Indeed, this form appears to contain a premature termination codon
as shown in Fig. 2 (TRANS00000039923).
Expression state information is an important aspect of the ASTD
database as it is used to analyze tissue-, developmental stage-, and
disease-speciﬁc expression of alternative transcripts. Expression
states in ASTD are derived from counts of cDNA/EST numbers in
libraries (see Materials and methods). Results from such analyses are
subject to well known limitations linked to cDNA library quality andFig. 3. Experimental validation of isoform expression for mucin 12, cell surface associated g
transcripts (anatomical system and pathology). For each ASTD variant, TPM (transcript per m
tissues are presented. Transcript TRAN00000086743 is predicted to be colon tumor-speciﬁ
binding sites for RT-PCR validation. TRAN00000086743 has a skipped exon (exon 8; 77 bp). C
lung and cervix and healthy peripheral blood cells; PCR band 453 bp in length represents TR
system to amplify cDNAs of housekeeping glyceraldehyde-3-phosphate dehydrogenase gene
cDNA). D: RT-PCR Validationmap of TRAN00000086742 and TRAN00000086743. The validat
hand side and a set of human colon, lung, cervical carcinoma cell lines (probing panel II) onconstruction methods [16,17]. However these analyses have repeat-
edly proven to be useful as indirect indications of expression biases
[18,19,20,21,22]. The ASTD server provides various analysis tools that
enable researchers to identify alternative transcripts of special
biological interest, using two major query modes. First, from the
main page, users can perform text search using ASTD identiﬁers, gene
names, gene symbols, Ensembl IDs, UniProtKB entry names and
accession numbers, UniProtKB/Swiss-Prot and UniProtKB/TrEMBL
cross-references, EMBL evidence, tissues, pathologies, developmental
stages, etc. Alternatively, an advanced search mode enables multi-
criteria searches based on chromosome location, splicing events, GO
(Gene Ontology) terms or gene expression patterns based on eVOC (a
controlled vocabulary for unifying gene expression data [23])
annotation. In the latter “gene expression” mode, users can select
two complex pools of tissues, developmental stage or pathologies, and
obtain all alternative transcripts that are speciﬁcally expressed in one
of the pools but not in the other. An overview of the expression states
of all transcripts from a given gene can be displayed in the form of a
digital expression map. This heatmap display enables a quick visual
inspection of expression biases relative to anatomical systems,
pathologies or developmental stages. Two expression maps (relative
to anatomical system and pathology) for the human mucin 12, cell
surface associated gene (MUC12) are shown in Fig. 3A. Users can also
combine anatomy and pathology terms in a single expression map.
Experimental validation
Our project had a signiﬁcant emphasis on the experimental
validation of predicted transcripts using reverse-transcription (RT)-
PCR. We completed the experimental validation of over 500 different
polyadenylation [24] and splicing (results herein) events in human
and mouse that were not previously described in the literature. For
polyadenylation sites, our validation efforts focused on events
conserved between human and mouse and producing alternative 3′
isoformswith size variations of 3 kb ormore. Out of 86 such events, 84
were individually conﬁrmed using a specially devised RT-PCR strategy
[24]. For splice variants, we focused on the identiﬁcation of cancer-
speciﬁc events in human. From a list of 419 ASTD-predicted tissue-
speciﬁc splice events for colorectal and/or lung cancer cells (Supple-
mentary Table 6), we conﬁrmed the existence of 370 independent
events. With the objective of identifying new biomarkers for the
detection of cancer cells, we further analyzed splice events occurring
speciﬁcally in cancer cell lines/tissues. Among the validated splice
events, 68 were detected in colorectal and/or lung cancer cell lines but
not in normal colon mucosae and/or the analyzed normal lung. These
cancer-speciﬁc splice events will represent a valuable source for
further validation of colorectal and/or lung cancer biomarkers. Splice
variant validation is presented in more detail in Supplementary
Document 2.
Fig. 3 shows validation detail for the human MUC12 gene. The digital
expression map obtained from the ASTD database (Fig. 3A) shows that
while this gene is mainly expressed in the colon, transcript
TRAN00000086743 ispredicted tobe colon tumor-speciﬁc. This transcript
(Fig. 3B) lacks exon 8 relative to transcript TRAN00000086742 which
should be present in colorectal normal and cancer cells. RT-PCR
experiments conﬁrmed these predictions. The transcript including exon
8wasmainly detectable in colon cell lines and normal colon tissueswhile
the skipped exon transcript was present in colorectal cancer cell lines andene MUC12 (Ensembl ID ENSG00000169887.2). A: Digital expression proﬁle of MUC12
illion) expression values based on the numbers of supporting EST/cDNA from all relevant
c. B: Exon/intron structure of TRAN00000086742 and TRAN00000086743 and primer
: RT-PCR results in normal human tissues vs. human cancer cell lines of the colorectum,
AN00000086742; TRAN00000086743 is conﬁrmed by the 376 bp PCR fragment. A PCR
GAPDH was used as loading control. NTC: non-tissue control (negative control without
ion data is subdivided into a set of pooled human cell lines (probing panel I) on the right-
the left-hand side.
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218 G. Koscielny et al. / Genomics 93 (2009) 213–220absent in allﬁve testednormal colon samples (Fig. 3C). PCRvalidationdata
are incorporated in the ASTD database in the form of graphical overviews
showing positive/negative PCR results for each tested splice variant and
condition (Fig. 3D).
Availability and future directions
The ASTD database can be accessed at http://www.ebi.ac.uk/astd
and is available for export as ﬂat ﬁles containing all features under
EMBL, GFF, GTF, BED, Excel and Fasta formats. Data can be obtained
separately for each species. Update plans involve quarterly runs of the
ASTD pipeline in order to represent newly generated transcribed
sequences. Our objective is that within two years, the alternative
transcript prediction, display and querying functionality of ASTD
should be an integral part of the Ensembl database [14].
Materials and methods
Alternative transcripts are derived using a three-stage procedure.
The genomic sequences used in ASTD 1.1 for Homo sapiens, Mus
musculus and Rattus norvegicus are respectively based on NCBI human
genome assembly build 36, NCBI mouse genome assembly build 36
and RGSC rat genome assembly build 3.4. The Ensembl gene sets
referenced in ASTD 1.1 for H. sapiens, M. musculus and R. norvegicus
come respectively from the Ensembl version 41, Ensembl version 41
and Ensembl version 42 gene builds.
Splicing variants
We generated splicing isoforms and alternative splice events using
AltSplice, an automated computation pipeline for human, mouse and
rat data [25]. Brieﬂy, introns/exons, splicing isoforms and alternative
splice events (cassette exons, mutually exclusive exons, etc.) are
predicted through mapping of EST, cDNA and mRNA sequences from
the standard, EST and high throughput cDNA (HTC) divisions of DDBJ/
EMBL/GenBank [26] onto genomic sequences centred around Ensembl
genes +/−10 kb. Mapped transcripts from EMBL release 88 include
8,125,884 human, 4,935,071 mouse and 824,394 rat sequences.
Typically, less than 25% of mapped transcripts are retained as supports
for splice variants in ASTD after ambiguous, incomplete and unspliced
matches are discarded.Fig. 4. TSS identiﬁcation and clustering scheme. Two transcripts from a single gene are shown
thick arrow. TSSs are represented with a thin arrow. Groups of TSSs are identiﬁed in the 10
cDNA alignments. Crossed out TSS elements are discarded as they align outside of the ﬁrstPolyadenylation variants
We identiﬁed polyadenylation variants and mapped them to
individual splice variants as described in Le Texier et al. [12]. First,
polyadenylation sites were identiﬁed at the 3′ end of each splice
variant from the previous stage, requiring support by poly(A)/poly(T)
terminated ESTs and the presence of a known poly(A) signal. Other
poly(A) sites were predicted independently of splice variants based on
a completemapping of Genbank 3′ ESTs and full length cDNAs fromH-
InvDB [27] and FANTOM 3 [10] to genomic sequences. Criteria for
inclusion of these splice variants include checks for internal priming
sites (genomic poly(A) stretches), unmatched transcript ends and
presence of a known polyadenylation signal, as described previously
[28]. Poly(A) sites from both pipelines were then merged.
TSS variants
We identiﬁed TSSs for each transcript using oligo-capped full-
length cDNA libraries. Transcript sequence sources are provided in
Supplementary Table 2. Similarly to other studies ([29] and [30]), TSSs
are deﬁned as genomic positions matching the 5′ end of an oligo-
capped cDNA and located either in the 5′ exon of a transcript or
upstream. Here we used regions up to ten kilobases upstream of each
splice variant. These regions were each aligned to the oligo-capped
cDNA sequences using the NCBI-Blast program. The high-scoring
segment pairs (HSP) with at least 95% identity were extracted and
ﬁltered according to the following additional criteria:
• Unambiguous match of cDNA to a single genomic region (the
upstream-most HSP is considered, thereby deﬁning the longest
possible transcript);
• 3′ end of cDNA located downstream of the deﬁned 5′ untranslated
region (UTR);
• HSP covering N90% of cDNA.
When several TSS are present, we cluster TSSs into “promoter
regions”. The distribution of inter-TSS distances is shown in Supple-
mentary Fig. 3. Inter-TSS distances seldom exceed 500 bp in human and
300 bp inmouse. Based on this observation and on a previous analysis of
5′ end sequences in full-length cDNAsbyKimura et al. [29], we deﬁned a
promoter region as a TSS cluster with no gap over 500 nt. We did not
cluster rat TSSs as most rat transcripts had a single TSS due to limited. Exons are represented by boxes and introns by lines. TSS clusters are representedwith a
kbp UTR region (including ﬁrst exon) of transcripts A and B based on the oligo-capped
exon and 10 kb upstream region.
219G. Koscielny et al. / Genomics 93 (2009) 213–220cDNA coverage. Fig. 4 gives an example of the identiﬁcation and
clustering of TSSs. The 3′-most TSSs of transcripts A and B were not
considered as they aligned outside of the ﬁrst exons and 10 kb upstream
regions. TSS clustering thenproduced a single cluster for each transcript.
Procedures for alternative transcript derivation are detailed in
Supplementary Document 1. Supplementary Table 3 summarizes the
numbers of ESTs, cDNAs and mRNAs used to support the different
transcript variants in each species.
Digital expression maps
Expression states were inferred from the clone library information
associated with each mRNA or EST sequence that supported a given
transcript. EST/cDNA sequences supporting several isoforms were
assigned to each compatible isoform. Human and mouse expression
states are based on the eVOC ontologies for anatomical systems,
pathologies and development stages [23]. eVOC associates clone
libraries and their corresponding sequences to controlled terms in an
organized set of hierarchical vocabularies. Because there is no
controlled vocabulary mapping for rat, as yet, we based our mapping
on Medical Subject Headings (MeSH) developed by the US National
Library of Medicine. We associated anatomy and disease vocabulary to
rat cDNA libraries using a semi-automatic learning process. We
grouped the developmental stages terms of rat and mapped them
ontoWitschi's embryonic development classiﬁcation [31] insteadof the
Theiler mouse-speciﬁc stages. We dealt with any ambiguity in library
terms using a custom-made dictionary where enough informationwas
available. General anatomical terms such as “head” or whole tissue
terms like “brain” constituted of several cell types were associated to
the equivalent ormost speciﬁc term in the hierarchy. In all species, ESTs
or cDNAs from mixed or pooled tissue libraries were discarded.
Supplementary Table 4 provides numbers of analyzed libraries and
extracted ontology terms for the three species studied. Tissue
representation in EST/cDNA libraries from each organism is presented
in Supplementary Figs. 1 and 2. As expected, some tissues are covered
very differently in different species. For instance, lung is among the
top ten tissues in human and rat while it is seldom represented in
mouse, in terms of number of libraries (Supplementary Fig. 1) as well
as of number of ESTs (Supplementary Fig. 2).
We derived expression data for three types of expression states
described in cDNA libraries, namely anatomy, pathology and develop-
ment. We used normalized transcript digital expression values,
introduced by the NCBI to mine UniGene for tissue/disease speciﬁcity
[32]. These values are expressed inTPM (transcript permillion). The TPM
values of transcripts are calculated as follows: for any transcript, divide
the number of EST evidences found in a particular expression state (e.g.
“lung”) by the total numberof ESTs from the cDNA libraries related to this
expression state. The resulting value is then normalized to one million.
We measured fold changes in the expression of a transcript in a
given expression state by dividing TPM in this state by the average
TPM expression value of this transcript in all expression states. The
digital differential expression signiﬁcance was then measured using a
t-test with a p-value cut-off of 0.05, applying a Benjamini–Hochberg
correction for a false discovery rate of less than 5%. This produced a
ﬁnal set of 38%, 22% and 19% signiﬁcant differentially expressed
isoforms for human, mouse and rat, respectively, between two
conditions (for example, normal vs. cancer). For each transcript, an
“expression analysis” page (Supplementary Fig. 4) displays TPM, fold
change between states and p-value of differential expression for each
type of expression state (anatomy, development and pathology).
Derivation of other data
Conserved alternative splicing
ASTD identiﬁes pairs of orthologous transcripts in any combination
of human, mouse or rat displaying conserved splice junctions andconserved splice events, as deﬁned by Thanaraj et al. [33]. First, we
identify conserved splice junctions that are conserved between genes
in the human and mouse AltSplice data sets by examining mouse
AltSplice transcript sequences (that are already mapped to a mouse
gene) for homology to exon sequence constructs around human
AltSplice splice junctions. An exon sequence construct is built by
concatenating two components: the 5′ component being the 70 nt
sequence from the 3′ end of the 5′ exon and the 3′ component being
the 70 nt sequence from the 5′ end of the 3′ exon. Amouse genewhose
transcriptome data shows at least three splice junctions conserved
with those from the human gene is considered as orthologous to the
human gene in question. Similarly, mouse transcript patterns are
considered as orthologous to a human transcript pattern if at least
three splice junctions are conserved between the two.
SNPs
We identiﬁed SNP positions based on dbSNP [34] as previously
reported in [12]. We aligned SNPs from the dbSNP databank to each
ASTD transcript to identify exonic SNPs and their allele usage by
examining each corresponding nucleotide of the EST/mRNA that
supported the transcript sequence. We derived allele-usage frequen-
cies at each SNP position and deduced SNPs with signiﬁcant
differences in allele usage among the transcripts. Such SNPs may
therefore mediate the regulation of alternative splicing. Users can
visualize SNPs associated to each transcript variant.
Peptides
For each variant transcript we derived the corresponding peptide
sequences, domain and functional site signatures obtained from Inter-
ProScan [35] aswell as synonymous andnon-synonymous SNPs. Theweb
interface presents the longest CDS of each splice variant by default. A link
to the other possible translations is provided (note that the other CDS are
not necessarily in frame with the longest CDS for the entire gene).
Premature termination codons (PTC)
In the coding sequence of ASTD transcripts, we annotate as PTC
nonsense codons located more than 50 nucleotides upstream of any
exon–exon junction [36].
MicroRNA targets
Target sites were obtained from the ElMMo miRNA target
prediction server (inference method developed by Gaidatzis et al.
[37]). Because microRNA targets were originally predicted on mRNA
sequences from NCBI RefSeq, we mapped the target positions on the
mRNA sequences back to the gene sequences in ASTD.
Experimental validation
We conﬁrmed alternative polyadenylation events using an ad-hoc
PCR strategy. Brieﬂy, we extracted mRNAs from 25 mouse tissues and
cell lines and we designed three speciﬁc RT-PCR probe sets for the
ampliﬁcation of: (i) independent 3′ ends; (ii) tandem 3′ ends and (iii)
very long 3′ UTRs (over 4.5 kb). Detailed protocols are given in [24]. For
alternative splicing events validation, we obtained mRNAs from 19
human tissues and 95 cell lines. Existence and expression proﬁle of
selected events for validationwere analyzed with speciﬁc RT-PCR using
cDNAs fromtwodifferent tissue/cell linepanels. Theﬁrst panel consisted
of pooled cell lines representing 19 different tissue origins. When
splice events were detected, a second probing panel was analyzed. PCR
product integrity and fragment sizes were veriﬁed on agarose gels. A
detailed protocol is provided in Supplementary Document 2.
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